© 2021 MJH Life Sciences and HCPLive - Clinical news for connected physicians. All rights reserved.
© 2021 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
Adam Friedman, MD, FAAD provides insight into how and why insurance companies implement non-medical therapeutic switching and what healthcare providers can do to mitigate its impact on patient care.
March 19th 2021
Adam Friedman, MD, FAAD defines non-medical therapeutic switching and discusses common tactics payors use to pressure practitioners and patients to switch.
An expert in dermatology discusses the potential impact of non-medical switching to biosimilars and generic formulations on safety and efficacy profiles.
March 26th 2021
Adam Friedman, MD, FAAD provides insight into how non-medical therapeutic switching affects clinical, economic, and psychological outcomes for patients.
A key opinion leader emphasizes the importance of discouraging non-medical switching by communicating with patients and partnering with industry researchers.
April 2nd 2021
Adam Friedman, MD, FAAD discusses how payors accelerated non-medical switching during COVID-19 and how healthcare providers can respond to new challenges.